US Pharma MarketingThe post First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy appeared first on Clinical Trials Arena.
First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene therapy for children with hearing loss linked to GJB2 gene changes. The post First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy appeared first on Clinical Trials Arena .
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene therapy for children with hearing loss linked to GJB2 gene changes.
Source: Clinical Trials Arena